Products

Peptide Vector Families
The technological platform developed by VECT-HORUS and the funnel approach allow the selection of sub-libraries of peptides. These peptide families are then validated in vitro, and in vivo (animal models) after chemical optimization, for their capacity to cross the physiological barriers.

Peptide vectors capable of transporting a load (tracking molecule) across the physiological barriers are developed as RMT-based peptide-vectors optimized at the pharmacological level (cleavable or labile bonds, cleavable disulfide bonds, coupling via a spacer arm, etc.). Depending on the options chosen by VECT-HORUS and the properties of its families of vectors, these are evaluated for their properties to vectorize drugs in development, or off-patent drugs on various animal models for brain pathologies (brain tumours, Parkinson’s disease, epilepsy, etc.).

Vector/Drug-Candidate Conjugates
Based on its families of vectors, VECT-HORUS adopts one of the two following strategies:

-Co-development with the (bio)pharmaceutical companies at the preclinical stage of customized vector/drug conjugates as patentable NCEs resulting from the conjugation of VECT-HORUS’ vectors, with: i) new lead drugs under development at the preclinical stage with poor BBB permeability prognosis, ii) drugs under development that failed at the beginning of clinical stage for lack of CNS bioavailability, iii) marketed drugs already used and protected by patents for a short time (life cycle management).

-In-house development of vector/drug conjugates, vectorization of off-patent drugs that leads to patented NCEs, with the aim of out-licensing them to (bio)pharmaceutical companies at preclinical development stages.